文献速递妇科

基于循环肿瘤DNA的肿瘤信息微小残留病灶检测在卵巢癌一线治疗中的预后价值

The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-11-22

该回顾性研究纳入31例新诊断II-IV期卵巢癌患者,采用全外显子测序鉴定个体化体细胞变异,并通过循环肿瘤DNA进行微小残留病灶检测。治疗前所有样本MRD阳性率为100%,治疗后降至25.8%;中位随访21.4个月,15例复发,治疗后MRD阳性患者中位无进展生存期显著短于阴性患者(5.8个月 vs 24.7个月,HR=6.678,p=0.01)。

要点

  • 治疗前MRD阳性率100%,治疗后降至25.8%,显示ctDNA检测高敏感性。
  • 治疗后MRD阳性患者中位PFS为5.8个月,阴性患者为24.7个月(HR=6.678,p=0.01)。
  • 治疗后MRD状态与复发强相关,MRD阳性组复发率更高。

核心结论

  • 通过ctDNA分析进行MRD检测是早期准确预测卵巢癌复发的有价值工具,可能改善临床结局。
  • 作者主张将MRD检测整合到常规临床实践中,以实现更有效和个性化的治疗策略。

研究设计与样本

  • 回顾性研究,2020年至2022年纳入31例新诊断II-IV期卵巢癌患者。
  • 所有患者完成标准治疗(细胞减灭术和铂类化疗)并达到完全缓解,未接受一线PARP抑制剂维持治疗。
  • 使用全外显子测序检测存档肿瘤组织及治疗前后血浆样本,以识别个体化体细胞变异用于MRD检测。

主要发现

  • 治疗前(基线)所有血液样本MRD阳性率为100%。
  • 治疗后(地标)样本MRD阳性率降至25.8%。
  • 中位随访至2023年9月为21.4个月,期间15例患者复发。
  • 治疗后MRD阳性患者中位无进展生存期显著短于MRD阴性患者(5.8个月 vs 24.7个月,HR=6.678,p=0.01)。
  • 治疗后MRD状态与复发强相关,MRD阳性组复发率更高。

临床怎么用

  • 作者主张将MRD检测整合到常规临床实践中,以实现更有效和个性化的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to assess the application and effectiveness of tumor-informed Minimal Residual Disease (MRD) detection using circulating tumor DNA (ctDNA) for predicting disease recurrence and survival outcomes in ovarian cancer patients. METHODS: Between 2020 and 2022, 31 newly diagnosed stage II-IV ovarian cancer patients were enrolled in this retrospective study. All patients completed standard treatment, including cytoreductive surgery and platinum-based chemotherapy, achieving a complete remission (CR) without receiving first-line PARP inhibitor maintenance therapy. Archived tumor tissue, as well as plasma samples collected pre- and post-treatment, were tested using Whole Exome Sequencing (WES) to identify personalized somatic variants for MRD detection. RESULTS: All pre-treatment (baseline) blood samples showed a 100 % MRD positive rate, demonstrating the high sensitivity of ctDNA-based MRD detection. This rate decreased to 25.8 % in post-treatment (landmark) samples, indicating a significant reduction of ctDNA levels following effective treatment. The median follow-up time until Sep 2023 was 21.4 months, during which 15 patients experienced recurrence. Landmark MRD-positive patients exhibited a markedly shorter median progression-free survival (PFS) compared to MRD-negative patients (5.8 months vs 24.7 months, HR = 6.678, p = 0.01). Furthermore, a strong correlation was observed between post-treatment MRD status and recurrence, with a higher relapse rate in the MRD-positive group. CONCLUSION: The study establishes MRD detection via ctDNA analysis as a valuable tool for early and accurate prediction of ovarian cancer recurrence, potentially leading to improved clinical outcomes. As a result, integrating MRD detection into routine clinical practice is advocated to enable more effective and personalized treatment strategies for ovarian cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Shu T, Liang Y, Zhang S, et al. The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer. Gynecol Oncol. 2024. PMID: 39579602. doi:10.1016/j.ygyno.2024.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。